February 29, 2016
Novocure Reports 2015 Operating Statistics and Financial Results
Year ended December 31, 605 active patients on Optune therapy at 2015 year end, an increase of 169 percent compared to 2014 year end Publication of EF-14 phase 3 pivotal trial results in the Journal of the American Medical Association concludes adding TTFields to maintenance temozolomide… Read More
learn more
February 29, 2016
Novocure Reports 2015 Operating Statistics and Financial Results
Year ended December 31, 605 active patients on Optune therapy at 2015 year end, an increase of 169 percent compared to 2014 year end Publication of EF-14 phase 3 pivotal trial results in the Journal of the American Medical Association concludes adding TTFields to maintenance temozolomide… Read More
learn more
February 29, 2016
Novocure Reports 2015 Operating Statistics and Financial Results
Year ended December 31, 605 active patients on Optune therapy at 2015 year end, an increase of 169 percent compared to 2014 year end Publication of EF-14 phase 3 pivotal trial results in the Journal of the American Medical Association concludes adding TTFields to maintenance temozolomide… Read More
learn more
February 23, 2016
Novocure to Present at Cowen and Company 36th Annual Health Care Conference
February 23, 2016 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure will present at Cowen and Company 36th Annual Health Care Conference on March 7, 2016, in Boston. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the… Read More
learn more
February 23, 2016
Novocure to Present at Cowen and Company 36th Annual Health Care Conference
February 23, 2016 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure will present at Cowen and Company 36th Annual Health Care Conference on March 7, 2016, in Boston. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the… Read More
learn more
February 23, 2016
Novocure to Present at Cowen and Company 36th Annual Health Care Conference
February 23, 2016 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure will present at Cowen and Company 36th Annual Health Care Conference on March 7, 2016, in Boston. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the… Read More
learn more
February 12, 2016
Anthem Inc. Issues Positive Coverage Decision For Optune in Newly Diagnosed Glioblastoma
Health insurance plans covering more than 97 million Americans now provide positive coverage of Optune Health insurance plans covering more than 97 million Americans now provide positive coverage of Optune February 12, 2016 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(… Read More
learn more
February 12, 2016
Anthem Inc. Issues Positive Coverage Decision For Optune in Newly Diagnosed Glioblastoma
Health insurance plans covering more than 97 million Americans now provide positive coverage of Optune Health insurance plans covering more than 97 million Americans now provide positive coverage of Optune February 12, 2016 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(… Read More
learn more
February 12, 2016
Anthem Inc. Issues Positive Coverage Decision For Optune in Newly Diagnosed Glioblastoma
Health insurance plans covering more than 97 million Americans now provide positive coverage of Optune Health insurance plans covering more than 97 million Americans now provide positive coverage of Optune February 12, 2016 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(… Read More
learn more
February 9, 2016
Novocure’s Phase 3 Pivotal Trial Results in Newly Diagnosed Glioblastoma Selected For ASCO’s Clinical Cancer Advances 2016 Report
February 09, 2016 11:21 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure’s (NASDAQ: NVCR) phase 3 pivotal clinical trial results of Tumor Treating Fields (TTFields) in combination with temozolomide in newly diagnosed glioblastoma (GBM) have been selected for inclusion in… Read More
learn more
